Maridebart cafraglutide
20210184
Phase 3 small_molecule active
Quick answer
Maridebart cafraglutide for Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active